13 results about "Decorin" patented technology

The invention discloses an application of core proteoglycan or a coding gene thereof as a target spot in preparation of psoriasis treatment drugs, and a series of experiments prove that DCN can effectively protect mouse psoriasis-like dermatitis induced by imiquimod, improve skin scale, erythema, thickening and epidermal abnormal differentiation, enhance the barrier function of skin, improve the curative effect of psoriasis, and improve the curative effect of psoriasis. A large amount of infiltration of inflammatory cells is reduced, and a certain anti-inflammatory effect is achieved. Experimental research shows that the DCN has an obvious drug effect on a psoriasis model, is safe and efficient, has no side effect, is simple in production process and has the potential of realizing medical transformation. And the potential application value of the DCN on other various skin inflammatory diseases can be expanded.

The invention discloses a virus-like structure nano adapter and application thereof, on the basis of hepatitis B virus core protein Uniprot P03146 of which nucleic acid binding domains at 145-183 sites of a C tail end are removed, CBP as shown in SEQ ID NO.01 is respectively inserted into a spike part and an N tail end of the hepatitis B virus core protein Uniprot P03146. The invention is constructed based on collagen combined polypeptide CBP designed by bionic decorrin, aims to imitate the interaction between natural decorrin and collagenous fiber, can efficiently cross over corneal epithelium barrier and repair corneal stroma in a non-photo-crosslinking manner, and solves the limitation of existing clinical treatment.

A pharmaceutical composition containing a stem cell secretion, and a pharmaceutically acceptable excipient thereof. The protein in the stem cell secretion comprises one, two or three proteins selected from a group consisting of a pigment epithelium-derived factor (PEDF), a tissue inhibitor of metalloproteinase 1 (TIMP-1), a secreted protein acidic and rich in cysteine (SPARC), an α2-HS glycoprotein (AHSG), a periostin (POSTN), a decorin (DCN), the retinoic acid receptor responder 2 (RARRES2), the glia-derived nexin (GDN), the Sparc / osteonectin, cwcv and kazal like domains proteoglycan 1 (SPOCK1), and the follistatin-like 1 (FSTL1). The pharmaceutical composition is used for treating degenerative ocular diseases including retinal degeneration, retinitis pigmentosa, glaucoma, macular degeneration, etc.

The present invention relates to an immune cell expressing a chimeric antigen receptor (CAR) and a heterologous decorin polypeptide and the medical use thereof in treaing cancer. In particular, the specification teaches a CD19 CAR- expressing T cell that secretes decorin.

Described herein are compositions (e.g., an inhibitory nucleic acid molecule) for reducing expression of decorin (DCN) and methods thereof for (i) treating a medical condition resulting from a myocardial infarction (Ml), and / or (II) promoting angiogenesis in a subject. The inhibitory nucleic acid molecule may be a small interfering RNA (siRNA), a double-stranded RNA (dsRNA), an anti-sense oligonucleotide (ASO), a microRNA (miRNA), or a short hairpin RNA (shRNA)), or a gapmeR described herein, or a composition (e.g., pharmaceutical composition) thereof. Advantageously, the composition described herein provides therapeutic effects (e.g., angiogenesis) for cardiac tissue following myocardial infarction (Ml).

Decorin or a composition containing decorin for use in the treatment of type 1 diabetes, type 2 diabetes or gestational diabetes is described herein. Decorin or a composition containing decorin is also described for use in the context of transplanting pancreatic islet cells.

The present invention relates to homing peptide-directed decorin conjugates for the treatment of epidermolysis bullosa, and corresponding methods of treatment. The use of novel homing peptides enables the targeting of the conjugates in vivo to specifically home to the skin and skin wounds by systemic administration.

The present disclosure pertains to a cell that expresses at least one binding protein, such as decorin binding protein A (DbpA), decorin binding protein B (DbpB), or combinations thereof. The cell may include immune cells, such as chimeric antigen receptor T-cells. The present disclosure also pertains to methods of treating or preventing a disease in a subject by administering a cell of the present disclosure to the subject. The present disclosure also pertains to methods of forming the cells of the present disclosure by expressing at least one binding protein in the cell.

Described herein are compositions (e.g., an inhibitory nucleic acid molecule) for reducing expression of decorin (DCN) and methods thereof for (i) treating a medical condition resulting from a myocardial infarction (Ml), and / or (ii) promoting angiogenesis in a subject. The inhibitory nucleic acid molecule may be a small interfering RNA (siRNA), a double-stranded RNA (dsRNA), an anti-sense oligonucleotide (ASO), a microRNA (miRNA), or a short hairpin RNA (shRNA)), or a gapmeR described herein, or a composition (e.g., pharmaceutical composition) thereof. Advantageously, the composition described herein provides therapeutic effects (e.g., angiogenesis) for cardiac tissue following myocardial infarction (Ml).

Decorin or a composition containing decorin for use in the treatment of type 1 diabetes, type 2 diabetes or gestational diabetes is described herein. Decorin or a composition containing decorin is also described for use in the context of transplanting pancreatic islet cells.

The present invention discloses the use of decorin or its encoding gene as a target in the preparation of a psoriasis treatment drug. Through a series of experiments, the present invention demonstrates that DCN can effectively protect against imiquimod-induced psoriatic skin inflammation in mice, improve skin scaling, erythema, thickening, and abnormal epidermal differentiation, enhance the skin's barrier function, reduce the infiltration of inflammatory cells, and exert a certain anti-inflammatory effect. The experimental studies of the present invention have confirmed that DCN has significant efficacy in psoriasis models, is safe, highly effective, and has no side effects, and has a simple production process, showing the potential for medical transformation. This will also help expand the potential application value of DCN in various other inflammatory skin diseases.

Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof.

The present invention relates to multifunctional protein molecules comprising decorin and their uses. In particular, the present invention relates to multifunctional protein molecules comprising decorin and a targeting polypeptide such as an antibody, and methods for their production and uses.